Bristol-Myers To Partner With Simcere Pharma On Orencia SC In China

Biopharmaceutical company Bristol-Myers Squibb Co. (BMY) and China-based Simcere Pharmaceutical Group (SCR) said Thursday that they have agreed to jointly develop and commercialize the subcutaneous formulation of Bristol-Myers' rheumatoid arthritis drug Orencia or abatacept in China.

The agreement expands on the two companies' strategic relationship formed in 2010. Financial terms of the deal were not disclosed.

Under the terms of the deal, Simcere will perform and fund all development and regulatory activities required to obtain market approval for Orencia SC in China. The companies will share responsibility for commercializing Orencia, and will share profits and losses related to the drug in China. Orencia SC is already on the market for the treatment of rheumatoid arthritis in the U.S., Europe and Japan.

Hongquan Liu, CEO of Simcere said, "Orencia SC is the third program in our R&D collaboration with Bristol-Myers Squibb, underscoring our joint commitment to our broad strategic partnership. Combining Orencia SC with our existing portfolio in rheumatoid arthritis treatment, we are committed to delivering more innovative and effective medicines to Chinese patients."

Beatrice Cazala, executive vice president, Commercial Operations, Bristol-Myers said, "If successful, not only could Orencia SC bring a new option to Chinese patients suffering from rheumatoid arthritis, but also it could become Bristol-Myers Squibb's first biologic medicine for the Chinese market."

In early March, Simcere said its board received a non-binding proposal letter from a consortium led by founder chairman Jinsheng Ren, to acquire all of the outstanding ordinary shares of the company for $9.56 per American Depositary Share or ADS or $4.78 per ordinary shares in cash.

BMY closed Thursday's trading at $47.17, up $0.60 on a volume of 8.51 million shares, while SCR closed trading at $9.40, down $0.03 on a volume of 1,400 shares.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Cuisine Solutions is recalling its JUST Egg flavored plant-based "bites" products due to undeclared allergens, the U.S. Food and Drug Administration said. The recall involves a limited number of 2-pouch retail packages that may contain an incorrect sealed pouch containing whole-egg and milk products, known allergens. Hedge-fund billionaire William Ackman's Pershing Square Tontine Holdings Ltd. (PSTH) agreed to acquire 10% of Universal Music Group from French media conglomerate Vivendi (VIV.L, VIVEF.PK) for about $4 billion, the companies said in a statement on Sunday. The 737 MAX 10, Boeing Co.'s largest 737 Max model, is taking its maiden flight today, reports said citing people familiar with the matter. The flight after months of testing and certification will be around 10 a.m. local time from the Seattle area. The schedule could change depending on weather or other factors. Meanwhile, the jetliner is expected to enter commercial service in 2023.
Follow RTT